BX004
AXP000217.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Originator
- BiomX
- Sponsor
- BiomX
Names
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage (cocktail)
- Replication
- replicating
- Route
- inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06998043 | Study With Phage for CF Subjects With Pseudomonas Lung Infection | Recruiting | Phase 2 | 2025-07-02 | 2026-03 | 63 | Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis (CF) |
| NCT05010577 | Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection | Completed | Phase 1/2 | 2022-06-21 | 2024-03-10 | 43 | Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40593506 | Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial. | Nature communications | 2025 | name in title: BX004-A |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41760669 | Author Correction: Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial. | Nature communications | 2026 | name in title: BX004-A |
| PMID 40632642 | Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials. | Expert opinion on investigational drugs | 2025 | name in abstract: BX004-A |
Notes
Inhaled phage cocktail against Pseudomonas aeruginosa in cystic fibrosis. Phase 1b/2a NCT05010577 completed; phase 2b NCT06998043 under way. BX004-A is the drug product tested in the phase 1b/2a trial.
How to cite
BX004 (AXP000217.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000217.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.